Vaccine platform recombinant measles virus

Virus Genes

Volumn 53, Issue 5, 2017, Pages 733-740

  Mühlebach, Michael D ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Emerging infections; Life attenuated vector; Measles virus; Reverse genetics; Vector platform

Indexed keywords

DIHYDROLIPOAMIDE DEHYDROGENASE; GLYCINE DEHYDROGENASE (DECARBOXYLATING); GUANINE NUCLEOTIDE BINDING PROTEIN; MEASLES VACCINE; NUCLEOCAPSID PROTEIN; RIBONUCLEOPROTEIN; RNA POLYMERASE; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS VACCINE;

ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIKUNGUNYA VIRUS; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; GENOME SIZE; HELICOBACTER PYLORI; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MEASLES VIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONONEGAVIRALES; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; VACCINATION; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; IMMUNOLOGY; MEASLES;

ANIMALS; HUMANS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 85023746327     PISSN: 09208569     EISSN: 1572994X     Source Type: Journal    
DOI: 10.1007/s11262-017-1486-3     Document Type: Review

References (71)

1. R.A. Weiss, The Leeuwenhoek Lecture 2001, Animal origins of human infectious disease. Philos. Trans. R. Soc. Lond. B. 356(1410), 957–977 (2001). doi:10.1098/rstb.2001.0838
2. D. Naniche, Human immunology of measles virus infection. Curr. Top. Microbiol. Immunol. 330, 151–171 (2009)
3. D.N. Durrheim, N.S. Crowcroft, P.M. Strebel, Measles - The epidemiology of elimination. Vaccine 32(51), 6880–6883 (2014). doi:10.1016/j.vaccine.2014.10.061
4. P.A. Rota, W.J. Moss, M. Takeda et al., Measles. Nat. Rev. Dis. Primers. 2, 16049 (2016). doi:10.1038/nrdp.2016.49
5. D.L. Fisher, S. Defres, T. Solomon, Measles-induced encephalitis. QJM 108(3), 177–182 (2015). doi:10.1093/qjmed/hcu113
6. J.F. Enders, T.C. Peebles, Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc. Soc. Exp. Biol. Med. 86(2), 277–286 (1954)
7. Flint SJ, Racaniello VR, Rall GF (2015) Principles of virology, 4th edition
8. J.F. Enders, Development of attenuated measles virus vaccines. Am. J. Dis. Child. 103(3), 335 (1962). doi:10.1001/archpedi.1962.02080020347030
9. S.L. Katz, C.H. Kempe, F.L. Black et al., Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine. N. Engl. J. Med. 263, 180–184 (1960). doi:10.1056/NEJM196007282630408
10. J.S. Rota, Z.D. Wang, P.A. Rota et al., Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res. 31(3), 317–330 (1994)
11. A.J.F. Schwarz, Preliminary tests of a highly attenuated measles vaccine. Arch. Pediatr. Adolesc. Med. 103(3), 386 (1962). doi:10.1001/archpedi.1962.02080020398042
12. H.Q. McLean, A.P. Fiebelkorn, J.L. Temte et al., Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2013) 62(RR-04): 1–34
13. S. Ueda, Development of measles vaccines in Japan. Vaccine 27(24), 3230–3231 (2009). doi:10.1016/j.vaccine.2009.02.066
14. P.N. Burgasov, O.G. Andzaparidze, V.F. Popov, The status of measles after five years of mass vaccination in the USSR. Bull. World Health Organ. 49(6), 571–576 (1973)
15. J.K. Rose, Complete intergenic and flanking gene sequences from the genome of vesicular stomatitis virus. Cell 19(2), 415–421 (1980). doi:10.1016/0092-8674(80)90515-2
16. A.K. Pattnaik, G.W. Wertz, Replication and amplification of defective interfering particle RNAs of vesicular stomatitis virus in cells expressing viral proteins from vectors containing cloned cDNAs. J. Virol. 64(6), 2948–2957 (1990)
17. P. Calain, L. Roux, The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 67(8), 4822–4830 (1993)
18. J. Curran, D. Kolakofsky, Replication of paramyxoviruses. Adv. Virus Res. 54, 403–422 (1999)
19. M.J. Schnell, T. Mebatsion, K.K. Conzelmann, Infectious rabies viruses from cloned cDNA. EMBO J. 13(18), 4195–4203 (1994)
20. F. Radecke, P. Spielhofer, H. Schneider et al., Rescue of measles viruses from cloned DNA. EMBO J. 14(23), 5773–5784 (1995)
21. H. Schneider, P. Spielhofer, K. Kaelin et al., Rescue of measles virus using a replication-deficient vaccinia-T7 vector. J. Virol. Methods 64(1), 57–64 (1997)
22. A. Martin, P. Staeheli, U. Schneider, RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J. Virol. 80(12), 5708–5715 (2006). doi:10.1128/JVI.02389-05
23. M. Singh, M.A. Billeter, A recombinant measles virus expressing biologically active human interleukin-12. J. Gen. Virol. 80(Pt 1), 101–106 (1999). doi:10.1099/0022-1317-80-1-101
24. M. Singh, R. Cattaneo, M.A. Billeter, A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J. Virol. 73(6), 4823–4828 (1999)
25. R. Cattaneo, G. Rebmann, A. Schmid et al., Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J. 6(3), 681–688 (1987)
26. W.P. Duprex, S. McQuaid, L. Hangartner et al., Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J. Virol. 73(11), 9568–9575 (1999)
27. H.T. Ong, K. Hasegawa, A.B. Dietz et al., Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 14(4), 324–333 (2007). doi:10.1038/sj.gt.3302880
28. A. Zuniga, Z. Wang, M. Liniger et al., Attenuated measles virus as a vaccine vector. Vaccine 25(16), 2974–2983 (2007). doi:10.1016/j.vaccine.2007.01.064
29. M.A. Billeter, H.Y. Naim, S.A. Udem, Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr. Top. Microbiol. Immunol. 329, 129–162 (2009)
30. M. Rager, S. Vongpunsawad, W.P. Duprex et al., Polyploid measles virus with hexameric genome length. EMBO J. 21(10), 2364–2372 (2002). doi:10.1093/emboj/21.10.2364
31. B. Mrkic, J. Pavlovic, T. Rulicke et al., Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 72(9), 7420–7427 (1998)
32. C. Combredet, V. Labrousse, L. Mollet et al., A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J. Virol. 77(21), 11546–11554 (2003)
33. P. Devaux, V. von Messling, W. Songsungthong et al., Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 360(1), 72–83 (2007). doi:10.1016/j.virol.2006.09.049
34. H. Mok, X. Cheng, Q. Xu et al., Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. Open Virol. J. 6, 12–22 (2012). doi:10.2174/1874357901206010012
35. A. Zuniga, M. Liniger, T.N.A. Morin et al., Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum. Vaccin. Immunother. 9(3), 607–613 (2013)
36. A. Sawada, K. Komase, T. Nakayama, AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine 29(7), 1481–1490 (2011). doi:10.1016/j.vaccine.2010.12.028
37. I.D. Iankov, I.H. Haralambieva, E. Galanis, Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 29(8), 1710–1720 (2011). doi:10.1016/j.vaccine.2010.12.020
38. S. Brandler, C. Ruffie, C. Combredet et al., A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31(36), 3718–3725 (2013). doi:10.1016/j.vaccine.2013.05.086
39. K. Ramsauer, M. Schwameis, C. Firbas et al., Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15(5), 519–527 (2015). doi:10.1016/S1473-3099(15)70043-5
40. S. Brandler, M. Lucas-Hourani, A. Moris et al., Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl. Trop. Dis. 1(3), e96 (2007). doi:10.1371/journal.pntd.0000096
41. S. Brandler, C. Ruffie, V. Najburg et al., Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28(41), 6730–6739 (2010). doi:10.1016/j.vaccine.2010.07.073
42. H.-M. Hu, H.-W. Chen, Y.-J. Hsiao et al., The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. Hum Vaccin Immunother 12(7), 1678–1689 (2016). doi:10.1080/21645515.2016.1143576
43. I.S. Harahap-Carrillo, I. Ceballos-Olvera, J.R.-D. Valle, Immunogenic subviral particles displaying domain III of Dengue 2 envelope protein vectored by measles virus. Vaccines 3(3), 503–518 (2015). doi:10.3390/vaccines3030503. (Basel)
44. C. Swett-Tapia, L. Bogaert, P. de Jong et al., Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines. J. Gen. Virol. (2016). doi:10.1099/jgv.0.000523
45. J. Reyes-del Valle, G. Hodge, M.B. McChesney et al., Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen. J. Virol. 83(17), 9013–9017 (2009). doi:10.1128/JVI.00906-09
46. J.R. del Valle, P. Devaux, G. Hodge et al., A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J. Virol. 81(19), 10597–10605 (2007). doi:10.1128/JVI.00923-07
47. J. Reyes-del Valle, C. La Fuente, M.A. de Turner et al., Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J. Virol. 86(21), 11558–11566 (2012). doi:10.1128/JVI.01776-12
48. M. Satoh, M. Saito, K. Tanaka et al., Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse. Comp. Immunol. Microbiol. Infect. Dis. 33(6), e81–e88 (2010). doi:10.1016/j.cimid.2010.02.006
49. M. Guerbois, A. Moris, C. Combredet et al., Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 388(1), 191–203 (2009). doi:10.1016/j.virol.2009.02.047
50. M. Liniger, A. Zuniga, T.N.A. Morin et al., Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 27(25–26), 3299–3305 (2009). doi:10.1016/j.vaccine.2009.01.057
51. C. Lorin, L. Mollet, F. Delebecque et al., A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78(1), 146–157 (2004)
52. C. Lorin, L. Segal, J. Mols et al., Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Naunyn Schmiedebergs Arch Pharmacol 385(12), 1211–1225 (2012). doi:10.1007/s00210-012-0793-4
53. C. Lorin, F. Delebecque, V. Labrousse et al., A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23(36), 4463–4472 (2005). doi:10.1016/j.vaccine.2005.04.024
54. R. Stebbings, M. Fevrier, B. Li et al., Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS ONE 7(11), e50397 (2012). doi:10.1371/journal.pone.0050397
55. R. Stebbings, B. Li, C. Lorin et al., Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. Vaccine 31(51), 6079–6086 (2013). doi:10.1016/j.vaccine.2013.09.072
56. G. Gupta, V. Giannino, N. Rishi et al., Immunogenicity of next-generation HPV vaccines in non-human primates: measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine. Vaccine (2016). doi:10.1016/j.vaccine.2016.07.051
57. G. Cantarella, M. Liniger, A. Zuniga et al., Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 27(25–26), 3385–3390 (2009). doi:10.1016/j.vaccine.2009.01.061
58. A. Higuchi, H. Toriniwa, T. Komiya et al., Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese encephalitis virus. PLoS ONE 11(3), e0150213 (2016). doi:10.1371/journal.pone.0150213
59. A.H. Malczyk, A. Kupke, S. Prufer et al., A highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J. Virol. 89(22), 11654–11667 (2015). doi:10.1128/JVI.01815-15
60. Z. Wang, L. Hangartner, T.I. Cornu et al., Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19(17–19), 2329–2336 (2001)
61. M. Yoneda, Study of pathogenicity of Nipah virus and its vaccine development. Uirusu 64(1), 105–112 (2014). doi:10.2222/jsv.64.105
62. Y. Yamaji, T. Nakayama, Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine 32(35), 4529–4536 (2014). doi:10.1016/j.vaccine.2014.06.024
63. N. Escriou, B. Callendret, V. Lorin et al., Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology 452–453, 32–41 (2014). doi:10.1016/j.virol.2014.01.002
64. M. Liniger, A. Zuniga, A. Tamin et al., Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26(17), 2164–2174 (2008). doi:10.1016/j.vaccine.2008.01.057
65. D.L. Bolton, S. Santra, C. Swett-Tapia et al., Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine 30(41), 5991–5998 (2012). doi:10.1016/j.vaccine.2012.06.029
66. P. Despres, C. Combredet, M.-P. Frenkiel et al., Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 191(2), 207–214 (2005). doi:10.1086/426824
67. S. Brandler, P. Marianneau, P. Loth et al., Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J. Infect. Dis. 206(2), 212–219 (2012). doi:10.1093/infdis/jis328
68. B. Mrkic, B. Odermatt, M.A. Klein et al., Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J. Virol. 74(3), 1364–1372 (2000)
69. ClinicalTrials.gov, An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.: NCT01320176. https://clinicaltrials.gov/, 2012. Accessed 15 Nov 2016
70. S.P. Buchbinder, D.V. Mehrotra, A. Duerr et al., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881–1893 (2008). doi:10.1016/S0140-6736(08)61591-3
71. H. Meyer, G. Sutter, A. Mayr, Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72(Pt 5), 1031–1038 (1991). doi:10.1099/0022-1317-72-5-1031